Context Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
15
- Stock Symbol
-
CNTX
- Investments
-
2
- Share Price
-
$0.18
- (As of Friday Closing)
Context Therapeutics General Information
Description
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Contact Information
Website
www.contexttherapeutics.comCorporate Office
- 2001 Market Street
- Suite 3915, Unit 15
- Philadelphia, PA 19103
- United States
Corporate Office
- 2001 Market Street
- Suite 3915, Unit 15
- Philadelphia, PA 19103
- United States
Context Therapeutics Stock Performance
As of 13-Nov-2026, Context Therapeutics’s stock price is $0.18. Its current market cap is $16.6M with 91.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.18 | $0.20 | $0.18 - $3.62 | $16.6M | 91.9M | 1.48M | -$0.46 |
Context Therapeutics Financials Summary
As of 30-Sep-2026, Context Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (15,145) | 58,264 | (5,809) | (3,635) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (45,818) | (39,486) | (29,914) | (25,116) |
| Net Income | (43,888) | (36,124) | (26,725) | (23,964) |
| Total Assets | 36,538 | 68,494 | 98,127 | 16,063 |
| Total Debt | 207 | 112 | 219 | 0 |
Context Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Context Therapeutics Comparisons
Industry
Financing
Details
Context Therapeutics Competitors (3)
One of Context Therapeutics’s 3 competitors is Eureka Therapeutics, a Venture Capital-Backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Eureka Therapeutics | Venture Capital-Backed | Emeryville, CA | ||||
| A2 Bio | Venture Capital-Backed | Agoura Hills, CA | ||||
| Century Therapeutics | Formerly VC-backed | Philadelphia, PA |
Context Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Context Therapeutics Patents
Context Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250333499-A1 | Bispecific antibodies and methods of using the same | Pending | 30-Apr-2024 | ||
| WO-2025231017-A1 | Bispecific antibodies and methods of using the same | Pending | 30-Apr-2024 | ||
| US-20250332255-A1 | Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof | Pending | 30-Apr-2024 | ||
| WO-2025231015-A1 | Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof | Pending | 30-Apr-2024 | ||
| AU-2022360988-A1 | Anti-mesothelin antigen-binding molecules and uses thereof | Inactive | 06-Oct-2021 | A61P35/00 |
Context Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Context Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Context Therapeutics Investments (2)
Context Therapeutics’s most recent deal was a Corporate Asset Purchase with Link Immunotherapeutics (CT-95) for . The deal was made on 09-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Link Immunotherapeutics (CT-95) | 09-Jul-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Arno Therapeutics (Apristor Onapristone XR Drug) | 15-Jan-2018 | Corporate Asset Purchase | Buildings and Property |
Context Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Context Therapeutics FAQs
-
When was Context Therapeutics founded?
Context Therapeutics was founded in 2015.
-
Where is Context Therapeutics headquartered?
Context Therapeutics is headquartered in Philadelphia, PA.
-
What is the size of Context Therapeutics?
Context Therapeutics has 15 total employees.
-
What industry is Context Therapeutics in?
Context Therapeutics’s primary industry is Drug Discovery.
-
Is Context Therapeutics a private or public company?
Context Therapeutics is a Public company.
-
What is Context Therapeutics’s stock symbol?
The ticker symbol for Context Therapeutics is CNTX.
-
What is the current stock price of Context Therapeutics?
As of 13-Nov-2026 the stock price of Context Therapeutics is $0.18.
-
What is the current market cap of Context Therapeutics?
The current market capitalization of Context Therapeutics is $16.6M.
-
Who are Context Therapeutics’s competitors?
Eureka Therapeutics, A2 Bio, and Century Therapeutics are competitors of Context Therapeutics.
-
What is Context Therapeutics’s annual earnings per share (EPS)?
Context Therapeutics’s EPS for 12 months was -$0.46.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
